August 6, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under IFRS)

Company name: YUKIGUNI FACTORY CO., LTD.
Listing: Tokyo Stock Exchange
Securities code: 1375
URL: https://www.yukiguni-factory.co.jp/
Representative: Masafumi Yuzawa, President and CEO, Representative Director
Inquiries: Masayoshi Yoneyama, Deputy Division Director of Corporate Planning Division, General Manager, IR & Public Relations Department
Telephone: +81-25-778-0162
Scheduled date to commence dividends payment: -
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the First Three Months Ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Total income		Operating profit		Profit before tax		Profit	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	10,202	15.4	-433	-	-471	-	-306	-
June 30, 2025	8,838	-13.1	-719	-	-736	-	-640	-

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Three months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
June 30, 2026	-306	-	-301	-	-7.70	-7.70
June 30, 2025	-636	-	-622	-	-15.95	-15.95

(Reference)

	Revenue		Core operating profit		Core EBITDA		Core EBITDA margin
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	%
June 30, 2026	7,983	9.6	246	996.8	831	44.4	10.4
June 30, 2025	7,284	-1.8	22	-78.6	575	-15.5	7.9

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	35,286	13,713	13,713	38.9
March 31, 2026	37,686	14,770	14,770	39.2

2. Cash Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	4.00	-	19.00	23.00
Fiscal year ended March 31, 2027	-				
Fiscal year ending March 31, 2026 (Forecast)		5.00	-	15.00	20.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Forecast of Consolidated Financial Results for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Total income		Operating profit		Profit before tax		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Full year	56,910	6.5	4,140	-4.1	3,950	-5.8	2,540	-14.0

	Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Yen
Full year	2,540	-14.1	63.69

Note: Revisions to financial results forecasts most recently announced: None

(Reference)

	Revenue		Core Operating Profit		Core EBITDA		Core EBITDA Margin
	Millions of yen	%	Millions of yen	%	Millions of yen	%	%
Full year	39,640	4.7	3,960	-4.3	6,450	0.4	16.3

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates

- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	39,910,700 shares
As of March 31, 2026	39,910,700 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	27,878 shares
As of March 31, 2026	27,878 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	39,874,372 shares
Three months ended June 30, 2025	39,882,215 shares

∗ **Review of this financial report by certified public accountants or an audit firm: None**

∗ **Proper use of earnings forecasts, and other special matters**

(Caution concerning forward-looking statements)

The forward-looking statements, such as forecasts of financial results, included in this document are based on information available to the management as of the date of the document and certain assumptions that the management considers reasonable. The Company does not promise that forecasts will be achieved. Actual results may differ significantly due to a range of factors.

(Other special comments)

(1) The Company and its consolidated subsidiaries (together, "the Group") apply the International Financial Reporting Standards (hereinafter "IFRS").

(2) Core operating profit = Operating profit – IAS41 "Agriculture" applying effects – Other income and expenses – One-time income and expenses

(3) Core EBITDA = Core operating profit + Depreciation + Amortization

(4) Core EBITDA margin = Core EBITDA / Revenue

(5) The effect of applying IAS 41 "Agriculture" is to apply IAS 41 "Agriculture" to the production process of mushrooms, from preparation to harvest, and to measure the mushrooms as biological assets at fair value less costs to sell. The gains or losses from the changes in fair value are considered as the impact amount.

(6) Other income and expenses are mainly impairment loss and loss on disposal of fixed assets.

(7) One-time income and expenses are income and expenses that are not incurred in the normal course of business. There are no one-time income and expenses incurred during the three months ended June 30, 2025 or the three months ended June 30, 2026.

(8) Core operating profit, Core EBITDA and Core EBITDA margin are not indicators defined by IFRS, but the Group assumes these indicators are useful for investors to evaluate the Group's performance. These financial indicators exclude the effect of non-recurring gains / losses and items that do not adequately present the Group's performance relative to its competitors. Core operating profit, Core EBITDA, Core EBITDA margin should not be considered as indicators to replace the other indicators shown in accordance with IFRS because they do not include some of the items that affect the profit for the period, so they are subject to significant restrictions as means of analysis. Core operating profit, Core EBITDA, Core EBITDA margin disclosed by the Group may be less useful in comparison with the same or similar indicators of other competitors because they are calculated according to a different method from those of such other companies.

(How to obtain supplementary financial results briefing materials and financial results briefing details)

Supplementary financial results briefing materials are posted both on TDnet and our website on August 6, 2026.

Accompanying Materials – Contents

I. Qualitative Information for the First Three-Months Period of the Fiscal Year Ending March 31, 2027

1. Analysis of Operating Results

During the first three-months period of the fiscal year (April 1, 2026 to June 30, 2026), the domestic economy saw continued improvement in the employment and income environment; however, the impact of factors such as persistent inflation and exchange rate fluctuations on household finances and corporate activity remained a cause for concern. Meanwhile, companies continued to face an uncertain business outlook of geopolitical risks such as the situation in the Middle East, with energy price volatility spilling over into raw material prices.

In this economic environment, the Group recognizes that it is becoming even more important to ensure medium- to long-term growth and strengthen its business foundation. As part of these efforts, the Group is working to strengthen its research and development and business development structures. Specifically, effective November 1, 2025, we expanded the “Research & Development Office” into the “Research & Development Division” and established an organizational structure aimed at creating new value through focused investment in research activities. Additionally, effective April 1, 2026, we established a new “Business Development Division” tasked with developing new markets through new business and processed foods, as well as creating new business models, with the aim of strengthening the organizational framework that supports our sustainable growth. Furthermore, in July 2026, we opened “KINOKO MIRAI Lab,” a new research and development facility in the Kanto region. By strengthening collaboration with customers, universities, and other research institutions and promptly meeting market needs, we are working to enhance our research and development capabilities and foster innovation.

The Group will promote the creation of new value on both the research and development front and the business development front, while accelerating innovation through utilization of the new research and development facility, aiming to achieve medium- to long-term growth and the sustainable enhancement of corporate value.

Total income for the first quarter of the current consolidated cumulative period was ¥10,202 million (+15.4% year-on-year), of which revenue was ¥7,983 million (+9.6% year-on-year). Gross profit was ¥1,773 million (+24.2% year-on-year). Selling, general and administrative (SG&A) expenses were ¥2,235 million (+2.4% year-on-year).

As a result of the above, operating loss was ¥433 million (operating loss of ¥719 million in the same period of the previous year) and loss attributable to owners of the parent was ¥306 million (loss attributable to owners of the parent of ¥636 million in the same period of the previous year). In the current consolidated cumulative period, gains arising from changes in fair value related to the application of IFRS Agricultural Accounting (IAS 41) were included in total income of ¥2,218 million (+42.8% year-on-year) and the cost of sales of ¥2,963 million (+20.6% year-on-year).

[Business results for the first three months ended June 30, 2026]

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026	% Change year-on-year
Revenue	7,284	7,983	9.6
Gains arising from changes in fair value	1,553	2,218	42.8
Total income	8,838	10,202	15.4
Operating (loss)	(719)	(433)	-
(Loss) before tax	(736)	(471)	-
(Loss) attributable to owners of parent	(636)	(306)	-

The status of revenue by business segment during the current consolidated fiscal year is as follows.

[Mushroom business]

1) Maitake

For Maitake, which is healthy and rich in umami components, we are promoting further demand expansion by offering sales floor displays and cooking menu suggestions tailored to seasonal events, while communicating its appeal and versatility through convenient and delicious cooking ideas. In addition, leveraging our strength in an extensive product lineup, including a new core product featuring generously cut portions of our premium large-cluster Maitake, "Kiwami," we are striving to expand our market share and strengthen our premium brand strategy through product proposals that meet diverse consumer needs.

Unit sales prices decreased, but sales volume increased those compared to the same period of the previous year. Thus, revenue of the Maitake business was ¥3,947 million (+11.4% year-on-year).

2) Eryngii

We offer a wide variety of standard products in sizes ranging from small packs to large packs and are making product proposals that cater to increasingly diverse customer needs. In addition, we are promoting product development tailored to various uses and consumption occasions, including convenient sliced products, with the aim of expanding demand.

Sales volume and unit sales prices exceeded those compared to the same period of the previous year. Thus, revenue of the Eryngii business was ¥949 million (+5.0% year-on-year).

3) Buna-shimeji

We are developing sales strategies centered on 1-root products, promoting stable pricing, closely monitoring the fruit and vegetable market and its market trends, and flexibly introducing products such as 2-root products in different quantities according to supply and demand balance.

Sales volume and unit sales prices exceeded those compared to the same period of the previous year. Thus, revenue from the Buna-shimeji business was ¥1,756 million (+4.2% year-on-year).

4) Other mushrooms

As for button mushrooms, the Company continues to focus on achieving stable production and consistent quality, while strengthening sales through promotional activities and creating new demand in order to reinforce its business foundation. As a result, revenue from button mushrooms increased compared to the same period of the previous year. In addition, revenue from Hon-shimeji, Hatake-shimeji, and button mushrooms and exotic mushrooms handled by our overseas group companies also increased compared to the same period of the previous year. As a result of the above, revenue from other mushroom businesses was ¥1,219 million (+13.4% year-on-year).

[Other]

Other revenue is mainly derived from sales of health foods and the substrate activator. Revenue of health foods and the substrate activator remained strong during the first quarter of the current fiscal year. As a result, revenue from other businesses was ¥110 million (+48.5% year-on-year)

Revenue by business segment is as follows.

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026	% Change year-on-year
Mushroom business	7,209	7,873	9.2
Maitake	3,544	3,947	11.4
Eryngii	904	949	5.0
Buna-shimeji	1,685	1,756	4.2
Other mushrooms	1,075	1,219	13.4
Other	74	110	48.5
Total Revenue	7,284	7,983	9.6

2. Analysis of Financial Position

[Assets]

Total assets at the end of the first quarter of the current consolidated fiscal year (as of June 30, 2026) were ¥35,286 million (-¥2,400 million from the end of the previous consolidated fiscal year). Current assets were ¥8,617 million (-¥3,071 million from the end of the previous consolidated fiscal year). This was mainly due to decreases of ¥1,992 million in cash and cash equivalents, ¥596 million in biological assets due to gains arising from changes in fair value and ¥495 million in trade and other receivables, respectively. Non-current assets were ¥26,669 million (+¥671 million from the end of the previous consolidated fiscal year). This was mainly due to increases of ¥503 million in property, plant and equipment of ¥147 million in deferred tax assets, respectively.

[Liabilities]

Total liabilities at the end of the first quarter of the current consolidated fiscal year were ¥21,573 million (-¥1,342 million from the end of the previous consolidated fiscal year). Current liabilities were ¥10,266 million (-¥1,201 million from the end of the previous consolidated fiscal year). This was mainly due to decreases of ¥879 million in income taxes payable, ¥617 million in other liabilities and ¥589 million in liabilities for employee benefits, while an increase of ¥871 million in trade and other payables. Non-current liabilities were ¥11,307 million (-¥141 million from the end of the previous consolidated fiscal year). This was mainly due to a decrease of ¥126 million in borrowings as a result of scheduled repayments.

[Equity]

Total equity at the end of the first quarter of the current consolidated fiscal year were ¥13,713 million (-¥1,057 million from the end of the previous consolidated fiscal year). This was mainly due to a decrease of ¥1,064 million in retained earnings resulting from the recording of a quarterly loss and the payment of year-end dividends.

3. Analysis of Cash Flows

The balance of cash and cash equivalents at the end of the first quarter of the current consolidated fiscal year decreased by ¥1,992 million from the end of the previous consolidated fiscal year to ¥1,976 million. The status of each cash flow and their factors are as follows:

[Net cash flows from operating activities]

Funds used as a result of operating activities was ¥625 million (the amount used was ¥2,283 million in the same period of the previous year). This was mainly due to decreases of ¥596 million in biological assets and ¥498 million in trade, other receivables and an increase of ¥177 million in trade and other payables, while income taxes paid of ¥879 million, liabilities for employee benefits decreased by ¥589 million and loss before tax of ¥471 million.

[Net cash flows from investing activities]

Funds used as a result of investing activities were ¥428 million (the amount used was ¥127 million in the same period of the previous year). This was mainly due to the expenditure of ¥432 million for the acquisition of tangible fixed assets associated with equipment renewal for the mushroom business.

[Net cash flows from financing activities]

Funds used as a result of financing activities were ¥940 million (the amount used was ¥690 million in the same period of the previous year). This was mainly due to dividends paid of ¥751 million and repayments of long-term borrowings of ¥128 million.

4. Explanations about Forward-Looking Information Including Forecast of Consolidated Financial Results

The full-year forecasts of the consolidated financial results for the fiscal year ending March 2027 remain unchanged from the forecasts that were announced on May 11, 2026.

The earnings forecast is based on the information available at this time, and the actual financial results may differ due to various factors.

II. Summarized Quarterly Consolidated Financial Statements and Significant Notes

1. Summarized Quarterly Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	3,968	1,976
Trade and other receivables	2,679	2,183
Inventories	1,484	1,572
Biological assets	3,265	2,669
Income taxes receivable	17	17
Other current assets	273	198
Total current assets	11,688	8,617
Non-current assets		
Property, plant and equipment	17,698	18,202
Investment property	94	94
Goodwill and intangible assets	6,024	6,016
Right-of-use assets	219	229
Retirement benefit asset	158	171
Other financial assets	164	165
Deferred tax assets	1,594	1,742
Other non-current assets	42	46
Total non-current assets	25,997	26,669
Total assets	37,686	35,286

(Millions of yen)

	As of March 31, 2025	As of June 30, 2026
Liabilities		
Current liabilities		
Trade and other payables	2,726	3,598
Income taxes payable	880	1
Employee benefit accruals	2,256	1,667
Current portion of long-term borrowings	4,422	4,422
Lease liabilities	159	172
Provisions	217	71
Other financial liabilities	33	179
Other current liabilities	770	153
Total current liabilities	11,467	10,266
Non-current liabilities		
Borrowings	11,012	10,886
Lease liabilities	179	182
Deferred tax liabilities	150	132
Provisions	21	21
Other financial liabilities	84	84
Other non-current liabilities	0	0
Total non-current liabilities	11,448	11,307
Total liabilities	22,916	21,573
Equity		
Share capital	100	100
Capital surplus	(5,898)	(5,895)
Retained earnings	20,547	19,482
Treasury shares	(30)	(30)
Other components of equity	51	56
Total equity attributable to owners of parent	14,770	13,713
Total equity	14,770	13,713
Total liabilities and equity	37,686	35,286

2. Summarized Quarterly Consolidated Statements of Income and Comprehensive Income

(Summarized Quarterly Consolidated Statements of Income)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Income		
Revenue	7,284	7,983
Gains arising from changes in fair value	1,553	2,218
Total income	8,838	10,202
Cost of sales (*1)	7,410	8,429
Gross profit	1,428	1,773
Selling, general and administrative expenses	2,183	2,235
Other income	52	45
Other expenses	17	16
Operating (loss)	(719)	(433)
Finance income	44	9
Finance expenses	61	48
(Loss) before tax	(736)	(471)
Income tax expense	(95)	(164)
(Loss)	(640)	(306)
(Loss) attributable to		
Owners of parent	(636)	(306)
Non-controlling interests	(4)	-
(Loss) per share		
Basic (loss) per share (Yen)	(15.95)	(7.70)
Diluted (loss) per share (Yen)	(15.95)	(7.70)

Management believes that the information of “material costs, labor costs, etc.” facilitates comparison between the Group and competitors by users of financial statements. Therefore, we disclose the information voluntarily as a note in the summarized consolidated statements of income. “Material costs, labor costs, etc.” are the production costs of finished goods and purchasing costs of other goods sold by the Group, excluding the gains arising from changes in fair value recognized under IAS 41 “Agriculture”.

(*1) Components of cost of sales		
Material costs, labor costs, etc.	4,952	5,465
Gains arising from changes in fair value	2,457	2,963
Total	7,410	8,429

(Summarized Quarterly Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
(Loss)	(640)	(306)
Other comprehensive income (After tax effect deduction)		
Items that will not be reclassified to profit or loss		
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	0	0
Total of items that will not be reclassified to profit or loss	0	0
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	17	4
Total of items that may be reclassified to profit or loss	17	4
Total other comprehensive income (After tax effect deduction)	17	5
Comprehensive income	(622)	(301)
Comprehensive income attributable to		
Owners of parent	(623)	(301)
Non-controlling interests	0	-

3. Summarized Quarterly Consolidated Statement of Changes in Equity

Three months ended June 30, 2025 (From April 1, 2025 to June 30, 2025)

(Millions of yen)

	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	Total equity attributable to owners of parent	Non-controlling interests	Total
Balance at beginning of period	100	(6,067)	18,334	(7)	6	12,366	159	12,525
(Loss)	-	-	(636)	-	-	(636)	(4)	(640)
Other comprehensive income	-	-	-	-	12	12	5	17
Comprehensive income	-	-	(636)	-	12	(623)	0	(622)
Purchase of own shares	-	-	-	(32)	-	(32)	-	(32)
Share-based remuneration transactions	-	2	-	-	-	2	-	2
Dividends of surplus	-	-	(478)	-	-	(478)	-	(478)
Total	-	2	(478)	(32)	-	(508)	-	(508)
Balance at end of period	100	(6,065)	17,219	(39)	19	11,233	160	11,393

Three months ended June 30, 2026 (From April 1, 2026 to June 30, 2026)

(Millions of yen)

	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	Total equity attributable to owners of parent	Non-controlling interests	Total
Balance at beginning of period	100	(5,898)	20,547	(30)	51	14,770	-	14,770
(Loss)	-	-	(306)	-	-	(306)	-	(306)
Other comprehensive income	-	-	-	-	5	5	-	5
Comprehensive income	-	-	(306)	-	5	(301)	-	(301)
Purchase of own shares	-	-	-	-	-	-	-	-
Share-based remuneration transactions	-	2	-	-	-	2	-	2
Dividends of surplus	-	-	(757)	-	-	(757)	-	(757)
Total	-	2	(757)	-	-	(755)	-	(755)
Balance at end of period	100	(5,895)	19,482	(30)	56	13,713	-	13,713

4. Summarized Quarterly Consolidated Statements of Cash Flows

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
(Loss) before tax	(736)	(471)
Depreciation and amortization	555	587
Interest expenses	50	47
Loss (gain) on sale of fixed assets	(0)	-
Loss on retirement of fixed assets	13	7
Decrease (increase) in trade and other receivables	566	498
Decrease (increase) in inventories	(92)	(87)
Decrease (increase) in biological assets	769	596
Increase (decrease) in trade and other payables	(286)	177
Decrease (increase) in retirement benefit asset	(4)	(12)
Increase (decrease) in employee benefit liabilities	(863)	(589)
Other	(734)	(484)
Subtotal	(761)	269
Interest paid	(16)	(15)
Income taxes paid	(1,505)	(879)
Net cash provided by (used in) operating activities	(2,283)	(625)
Cash flows from investing activities		
Purchase of property, plant and equipment	(159)	(432)
Proceeds from sale of property, plant and equipment	0	-
Purchase of intangible assets	(5)	-
Other	37	4
Net cash provided by (used in) investing activities	(127)	(428)
Cash flows from financing activities		
Repayments of long-term borrowings	(128)	(128)
Repayments of lease liabilities	(54)	(60)
Purchase of own shares	(32)	-
Dividends paid	(474)	(751)
Net cash provided by (used in) financing activities	(690)	(940)
Effect of exchange rate changes on cash and cash equivalents	7	2
Net increase (decrease) in cash and cash equivalents	(3,094)	(1,992)
Cash and cash equivalents at beginning of period	3,903	3,968
Cash and cash equivalents at end of period	809	1,976

5. Notes to Summarized Consolidated Financial Statements

(Going Concern Assumptions)
Not applicable.

(Segment Information)
(1) Reportable segments
The Group's reportable segments are components of the Group for which separate financial information is available and regular evaluation by the Board of Directors, chief operating decision maker, is being performed in order to make decisions about resources to be allocated and to assess its performance.
The mushroom business is listed as a reporting segment as the Group has a comprehensive strategy for products and services and is expanding its business activities. "Other" includes businesses that are not included in the reportable segment.
The Group aggregates Maitake business, Eryngii business, Buna-shimeji business, etc. as a reportable segment, "mushroom business," in terms of similarity of economic characteristics such as revenue trends, and the following features are all similar in this segment: (a) the nature of products and services, (b) the nature of the production processes, (c) the type of customers of the products and the services, (d) the method used to deliver the products or provide the services, and (e) the nature of regulatory environment.

Description of the reportable segment is as follows:

	Description of business
Mushroom business	Production and sales of Maitake, Eryngii, Buna-shimeji and other mushrooms

(2) Reportable segments information
The accounting methods of reportable business segments are the same as the Group's accounting policies. Figures reported as segment profit are based on operating profit reported in the summarized consolidated statements of income. Revenues from intersegment transactions are based on the current market prices.

Three months ended June 30, 2025 (From April 1, 2025 to June 30, 2025) (Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	7,209	74	7,284	-	7,284
Intersegment revenue	-	-	-	-	-
Total revenue	7,209	74	7,284	-	7,284
Segment profit (loss)	(720)	(32)	(753)	34	(719)
Finance income					44
Finance expenses					61
Profit (loss) before tax					(736)

(*1) Adjustment items for segment profit (loss) include corporate expenses that are not allocated to each business segment.

Three months ended June 30, 2026 (From April 1, 2026 to June 30, 2026) (Millions of yen)

	Mushroom business	Others	Total	Adjustment items (*1)	Per consolidated financial statements
Revenue					
Revenue from external customers	7,873	110	7,983	-	7,983
Intersegment revenue	-	-	-	-	-
Total revenue	7,873	110	7,983	-	7,983
Segment profit (loss)	(420)	(14)	(435)	1	(433)
Finance income					9
Finance expenses					48
Profit (loss) before tax					(471)

(*1) Adjustment items for segment profit (loss) include corporate expenses that are not allocated to each business segment.

(Earnings per Share)

Calculation of basic earnings per share and diluted earnings per share are described below.

	(Unit)	Three months ended June 30, 2025	Three months ended June 30, 2026
Basic loss per share			
(Loss) attributable to owners of parent	(Millions of yen)	(636)	(306)
Profit not attributable to common shareholders of parent	(Millions of yen)	-	-
(Loss) used for calculation of basic loss per share	(Millions of yen)	(636)	(306)
Average number of common shares during the period	(Thousand shares)	39,882	39,874
Basic (loss) per share	(Yen)	(15.95)	(7.70)
Diluted loss per share			
(Loss) used for calculation of basic loss per share	(Millions of yen)	(636)	(306)
Adjustment	(Millions of yen)	-	-
(Loss) used for calculation of diluted loss per share	(Millions of yen)	(636)	(306)
Average number of common shares during the period	(Thousand shares)	39,882	39,874
Average number of common shares during the period after dilution	(Thousand shares)	39,882	39,874
Diluted (loss) per share	(Yen)	(15.95)	(7.70)

(Significant Subsequent Events)

Not applicable.